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Abstract
Background. The true incidence and prevalence of liver disease is diﬃcult to ascertain because there are few, if any, population-
based registers of liver disease available to ensure proper case and comparator selection. The epidemiology of liver disease in Tayside
(ELDIT) is a specially built register of liver disease for a well-deﬁned geographical area of Scotland.
Aims. This paper describes the electronic linkage of multiple data sources to form ELDIT and provides initial results from the
database.
Patients. All subjects resident in Tayside and registered with a general practitioner in the study period 1980–1999, approximately
400,000 people.
Methods. Electronic record-linkage techniques were employed to include anonymised data from primary and secondary sources.
Hospital admissions, dispensed medication, and laboratory results from immunology, virology, and biochemistry were used to
identify cases of liver disease. Diagnostic algorithms were used to verify and classify subjects with liver disease. A validation of the
algorithms against the clinical diagnosis was used to determine the measure of agreement (true positive rate) of ELDIT.
Results. At present approximately 10,000 subjects have been identiﬁed with liver disease or abnormal liver function. The data set
is nearing completion with cases of rarer liver disease being identiﬁed last. Incidence densities for the population were calculated.
From the validation study, agreement between electronic and clinical diagnosis was 0.98 and positive predictive value was 0.83
showing electronic diagnostic algorithms are sensitive enough to identify liver disease using para-clinical data.
Conclusions. ELDIT demonstrates how clinical information can be harnessed electronically to provide a better understanding of
liver disease in a population.
 2002 Elsevier Science (USA). All rights reserved.
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1. Introduction
Ascertainment of the true incidence and prevalence of
the manifestations of liver disease is a diﬃcult task, but
crucial to adequately identify research needs and assess
health resource implications. The deﬁnition of liver dis-
ease may range from minor abnormalities of liver func-
tion tests through to acute and chronic hepatitis, cirrhosis,
malignancy, and liver failure with its complications as-
sociated with the disease, such as variceal bleeding and
ascites. For the purposes of this research all types of liver
disease are relevant, as even minor abnormalities of liver
function may represent serious sub-clinical disease and
even if not are often associated with signiﬁcant health
resources costs to investigate for potentially serious liver
disease.
Biomedical informatics enables clinicians and
researchers to use patient speciﬁc information to
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investigate patient health, healthcare provision, and
health outcomes. Applying data manipulation and sta-
tistical techniques to obtain information from a data-
base, the discovery of regularities can be found, such as
the prevalence of disease over time, or the use of par-
ticular treatments of disease. Irregularities may also be
found, such as variations in clinical practices over time.
This ‘‘data mining’’ can also lead to the discovery of
patterns to guide research [1].
The challenge in this study was to duplicate clinical
diagnoses of liver disease using electronic biomedical
data sets. Electronic clinical decisions use para-clinical
data to formulate a diagnosis. The para-clinical data are
all laboratory results, all examination results, and pa-
tient diagnosis that is recorded electronically (e.g., hos-
pital discharge codes). It cannot include the opinion of
the clinicians themselves, other than that which is rep-
resented in a hospital discharge code, which is limited
and excludes out-patient clinics. Therefore, a series of
‘‘rules,’’ ‘‘questions’’ or ‘‘procedures’’ are followed
through the data set to form a diagnosis. This is known
as a diagnostic algorithm. Non-electronic clinical diag-
noses may take into account subjective and clinician
observed characteristics to determine the illness of the
patient. Electronic diagnostic algorithms for a liver
disease can be compared with clinical algorithms (gold
standard) by validation and thus determining a measure
of agreement.
The epidemiology of liver diseases in Tayside (EL-
DIT) Study Group is dedicated to evaluating the prev-
alence of diagnosed and undiagnosed liver disease in the
Tayside region of Scotland. This paper examines how
information from hospital/medical records, hospital
admissions, blood tests, histology results, and commu-
nity prescribing were record-linked to identify, describe,
and determine health care utilisation of subjects with
liver disease in Tayside.
2. Methods
Tayside is a geographically compact region of ap-
proximately 400,000 people that have health care ad-
ministered by 278 general practitioners, three acute
general hospitals (Ninewells Hospital and Medical
School, Perth Royal Inﬁrmary, and Stracathro General
Hospitals), and two health care trusts.
2.1. Patient identiﬁcation
Every patient who is registered with a general practi-
tioner (GP) in Scotland is allocated a unique 10 digit
identiﬁer called the community health number that is
centrally held and continuously updated. An anonymous
data set is made available to the Medicines Monitoring
Unit (MEMO) to determine the breakdown of the Tay-
side population, deaths, and patient migration. This in-
formation is particularly important when determining the
denominator for population-based analysis (incidence
and prevalence rates of disease in a population).
2.2. Data sources for electronic record-linkage
The community health number is used as the patient
identiﬁer in all healthcare activities in Tayside, both in
primary and secondary care. After anonymisation, we
record-linked the following independent data sources to
maximise the accuracy of diagnosis and disease ascer-
tainment.
2.2.1. Prescribing database
The Medicines Monitoring Unit has captured person
speciﬁc dispensing information for the whole of Tayside
since January 1993 and has been described elsewhere [2].
Brieﬂy, MEMO has devised a method of capturing
person speciﬁc dispensing for the whole of Tayside and
has recorded over 10 million prescription items speciﬁed
by an anonymised subject speciﬁc identiﬁer. All pre-
scriptions related to the treatment of liver disease and its
complications were identiﬁed for the study (e.g., spir-
onolactone, ursodeoxycholic acid, interferon, and cor-
ticosteroids).
2.2.2. Scottish morbidity records (SMR01, SMR04, and
SMR06)
This is a list of hospital discharges for all hospitals in
Scotland. In Tayside there are 63,000 hospital dis-
charges each year and the Medicines Monitoring Unit
holds the Tayside portion of the Scottish morbidity
record dating back to 1980. Admission records are co-
ded according to the International Codes for Disease
(ICD versions 9 and 10) and we identiﬁed patients
admitted to Tayside hospitals with a primary or sec-
ondary diagnosis of liver disease. In addition all SMR04
psychiatric data (alcohol dependency) and SMR06
(cancer registration) within Tayside further reﬁne
diagnoses.
2.2.3. Death registry
Details of all deaths in Tayside since 1989 are elec-
tronically recorded through a copy of the General
Registers Oﬃce-Death Certiﬁcation Database and held
within the MEMO. ELDIT identiﬁed all patients with
primary or secondary liver related diagnoses from this
register.
2.2.4. Carstairs categories for deprivation
The Carstairs score is a deprivation measure based on
data derived from the decennial census [3]. Its compo-
nent variables are the percentage of people in a postcode
sector with no car, the percentage living in overcrowded
housing, the percentage with the household held in semi-
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or unskilled occupations, and the percentage of men
unemployed.
2.2.5. Endoscopy database
All endoscopy reports in Tayside since 1975 have
been electronically recorded and held within MEMO.
All patients with varices and variceal bleeding have been
identiﬁed from this database.
2.2.6. Regional biochemistry database
Biochemical investigations for Tayside since 1989 are
held on a central database in the Department of Bio-
chemical Medicine in Ninewells Hospital. ELDIT
identiﬁed all abnormal alanine aminotransferase (ALT),
aspartate aminotransferase (AST), alkaline phosphatase
(ALP), total bilirubin, c-glutamyl transpeptidase
(GGT), serum iron and copper studies, and paracetamol
concentrations since 1989.
2.2.7. Pathology database
Results from all pathology investigations since 1990
for Tayside are electronically stored in MEMO. All re-
sults pertaining to liver disease were linked to the main
ELDIT database. In addition older liver biopsies were
searched manually and entered into the database.
2.2.8. Virology database
Computerised records exist for all requests for viral
serology for the hepatitis viruses for the Tayside region
since 1980.
2.2.9. Immunology database
Patient speciﬁc results of autoantibodies are stored
on a computerised immunology database. Patients with
positive autoantibodies speciﬁc to liver disease were
identiﬁed and linked to the ELDIT database.
2.3. Integration of data sources
A large analytic databasewas assembled by integrating
each of the above data sources. Each data source was
evaluated for the presence of one or more diagnostic cri-
teria for any of the liver diseases or complications. Indi-
viduals with diagnostic criteria in at least one database
had records from all possible data sources extracted and
put into the analytical database. Multiple records for in-
dividuals were brought together through deterministic
record-linkage using the anonymised subject identiﬁer as
the unique identiﬁer. The resultant database contained
single records per person with diagnostic information
transposed temporally across individuals.
2.4. Liver diseases of interest
Table 1 gives the liver diseases and complications that
were of primary interest to the ELDIT study group.
Diagnostic criteria for each liver disease and complica-
tion were compiled through review of medical literature
and collaboration with the specialist physician in liver
disease (hepatologist) for Tayside. Electronic algorithms
incorporating diagnostic criteria were used to identify
liver disease in the study population. The complexity of
the algorithms varied depending on the diagnostic cri-
teria of the liver disease. Simple algorithms can be used
for some liver diseases with highly speciﬁc diagnostic
criteria (the viral and malignant liver diseases for ex-
ample). Individuals are classiﬁed for the presence or
absence of each diagnostic criterion.
2.5. Details of electronic algorithms
The electronic algorithm is an event map that depicts
graphically the possible clinical results for a particular
outcome. Clinical data from biochemistry, pathology,
and immunology were mapped out logically to depict
the sequence of events that would take place to deter-
mine the presence of disease. For example, Fig. 1 shows
the electronic algorithm for the diagnosis of primary
biliary cirrhosis (PBC). The algorithm begins with re-
sults of an immunology test (anti-mitochondrial anti-
body); if positive, a liver biopsy along with cholestatic
liver function tests will conﬁrm the diagnosis. The elec-
tronic algorithm can be constructed with a notion of
time, if temporality is an issue with the disease. The
algorithms were designed and then validated with an
expert panel of liver disease specialists. The algorithms
were produced using DATA 3.5 for health care users
(Treeage Software, Williamstown, MA).
2.6. Application of electronic algorithms
Each individual within the analytic database was sent
through each diagnostic algorithm. Individuals may si-
multaneously have more than one type of liver disease,
or progress from one state of liver disease to another
over the time period of study. Therefore, separate dis-
ease status variables were set up for each liver disease
analysed. For liver disease identiﬁed through simple
Table 1
Liver disease and complications of interest to the ELDIT study group
Liver disease of interest Liver disease
complication
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algorithms, dichotomous (yes/no) variables were used.
For liver diseases identiﬁed through algorithms utilising
decision analysis methodology, continuous variables
were used representing the probability of having the
disease.
2.7. Validation of electronic algorithms
The specialist physicians (hepatologists) use past
medical history, laboratory test results, clinical obser-
vations, and expert knowledge of the disease to make a
clinical diagnosis of liver disease. The clinical diagnosis
(gold standard) recorded in hospital medical notes was
compared with the electronic algorithm diagnosis in
ELDIT for the same patient. The comparison was used
to validate the electronic algorithms and measure the
amount of agreement between ELDIT and the hepa-
tologists diagnosis.
In total, 200 subjects were randomly selected from the
ELDIT database. The ELDIT records were blinded of
diagnosis, identiﬁed only by community health index
(CHI) number and date of death (medical records of
dead people are held separately). The liver diseases in-
cluded in the validation were viral hepatitis (HCV,
HBsAg positive, and HAV), PBC, alcoholic liver dis-
ease, and heptocellular carcinoma. A research nurse
acquainted with medical records and specialist medical
terminology extracted the clinical diagnosis of liver
disease (gold standard) from the medical notes for the
ﬁrst 100 subjects on the random list. Medical records
that were not found in any hospital medical record
stores (Ninewells, Perth Royal Inﬁrmary, and Straca-
thro hospital) or destroyed records were excluded and
replaced with another randomly selected patient (next
on the list). If the medical notes had no recording of
liver disease in the medical record, they were assigned
‘‘nil in notes.’’ Only hospital medical records were used
to identify the diagnosis of liver disease, as ethical ap-
proval did not allow for contact with general practice.
Since clinician diagnoses by a specialist physician (hep-
atologist) may be considered the more accurate method
of identifying liver disease, discrepancies observed used
the clinician diagnosis as the deﬁnitive diagnosis. The
amount of agreement was calculated comparing ELDIT
with the gold standard (clinician diagnosis) as well as
positive predictive value for the algorithm diagnosis
used in ELDIT.
2.8. Ethical approval
The Tayside research and ethics committee approved
the study. The databases of the ELDIT study are reg-
istered under the Data Protection Act for the purposes
of research only. At all times conﬁdentiality of individ-
ual patients was maintained and patient speciﬁc data
were anonymised to the researcher. Patients community
health index numbers were revealed only for the vali-
dation study and then with ethics approval. All elec-
tronic media containing patient speciﬁc data met the
requirements of health service data protection and
encryption standards [4–6].
3. Statistical analysis
Analysis of data includes the incidence density over a
period of time. This is statistical measure of incidence;
the numerator is the number of new cases in the popu-
lation. The denominator is the sum of each individuals
time at risk or the sum of the time that each person
Fig. 1. Diagnostic algorithm for primary biliary cirrhosis (PBC).
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remained under observation and free from disease [7].
Inherent in this calculation is the idea that a given
amount of person-time can be derived from a variety of
populations in diﬀerent circumstances. Thus, observa-
tion of 16 people for 1 year, of 8 people for 2 years, or of
32 people for 6 months would all result in a total of 16
person-years of observation. The denominator repre-
sents only those patients that are registered with a GP in
Tayside. These patients are part of the population at the
beginning of the year of observation and allowed to die,
but are excluded if they move out of or into the area
within the year. The exclusion criteria are to ensure that
the cases are new or incident cases in the population at
risk. The population at risk was also taken to be those
people in Tayside over the age of 20 years to provide a
more stable denominator population.
4. Results
Through electronic record-linkage we have managed
to register on the ELDIT data set 1770 subjects using
the electronic diagnostic algorithms for speciﬁc liver
diseases. The group tested for HAV IgG only was ex-
cluded from this total because they represent pre-im-
munisation testing and other non-active liver diseases.
Further research into this group of people is necessary.
Approximately 7000 other subjects have been identiﬁed
with abnormal liver function tests (GGTP 75U/L,
ALTP 45U/L, and ALPP 150U/L) or hospitalised
with a discharge code for abnormal liver function test
(ICD9 code¼ 794.8). The implications of these abnor-
mal liver function tests are discussed later. Table 2 gives
the summary of the number of subjects found with each
liver disease in the population. The years in which the
subjects are collected and registered are also given in
Table 2. This is to provide an accurate base population
(population at risk) to calculate the incidence density of
each disease within the year interval. The number of
people in each year can be found using the Community
Health Master Patient Index and exclude those people
that move into or out of the area, this then becomes the
ﬁxed or static population for the denominator.
More than one data source was used to identify the
liver disease increasing the probability of deﬁnite dis-
ease. The ﬁnal data set will be analysed for completeness
using estimations calculated by capture–recapture
methodology [8].
Table 2
Frequency of liver disease in the ELDIT database
Liver disease Years Number of people Incidence density (person years)
Liver and intrahepatic bile duct cancer 1991–1995 117 5.93/105
Primary biliary cirrhosis 1980–1998 302 4.26/105
Hepatitis A (IgG and IgM) 1991–1997 4090 1.48/103
Hepatitis A IgG only 1991–1997 4004 1.45/103
Hepatitis A IgM only 1991–1997 86 3.12/105
% test positive/year 37:1 6:7%
Hepatitis B virus (HBsAg positive) 1991–1997 186 6.72/105
% test positive/year 1:0 0:8%
Hepatitis C virus 1991–1997 469 1.70/104
% test positive/year 6:0 1:5%
Alcoholic liver disease 1991–1995 325 1.64/104
Oesophageal varices 1989–1995 201 7.29/105
Ascites 1981–1995 589 9.96/105
Total 1770a
Abnormal liver function tests
GGT (675U/L) 1991–1997 13,491 4.89/103
ALP (P150U/L) 1991–1997 21,705 7.87/103
Bilirubin (P17lm/L) 1991–1997 23,962 8.69/103
Bilirubin (P50lm/L) 1991–1997 4230 1.53/103
ALT (P45U/L) 1991–1997 16,732 6.07/103
Albumin (630 g/L) 1991–1997 17,545 8.54/103
AST (P45U/L) 1991–1997 436 7.37/105
Total abnormal tests 72,871
Hospitalisation (ICD-9 code 794.8) 1981–1995 436 7.37/105
Abnormal GGT and ALPb 7457
Abnormal GGT and ALT 3734
Abnormal ALT and ALP 5448
aTotal patients registered with liver disease excluding HAV IgG only.
bAbnormal results for liver function tests recorded within 6 months of each other.
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4.1. Validation of ELDIT
There were 110 randomly selected cases validated by
the research nurse at the end of the validation study.
Table 3 gives the results comparing the case note results
with ELDIT electronic diagnostic algorithm. There were
18 ELDIT diagnoses that could not be validated with
hospital notes (nil in notes). These 18 patients were
identiﬁed by blood tests analysed in the hospital labo-
ratory but taken from and reported back to the patient
in general practice (primary care). These subjects have
not attended out-patient clinics or been hospitalised.
Further investigation of these subjects revealed that the
5 PBC patients were newly diagnosed women (>75 years
of age) and the HCV subjects were generally younger
males with little hospital contact. These subjects may
represent a group of asymptomatic people that are cared
and managed in primary care, while more severe cases
are seen in secondary care. Two cases of PBC were di-
agnosed in ELDIT, but their medical records found
other diagnoses. This illustrates where clinical diagnosis
of some diseases utilises more information than labo-
ratory data. Primary biliary cirrhosis, alcoholic liver
disease, and hepatitis C virus infection may lead to cir-
rhotic liver. Therefore it may be diﬃcult to diﬀerentiate
these diseases by laboratory tests alone. Clinical obser-
vations of the patient (HCV patients are generally young
men) and medical history (past drinking career) ﬁll in
the necessary gaps in information to make a positive
diagnosis.
Table 4 gives a summary of the validation study and
the agreement between the ELDIT diagnosis and
the clinical diagnosis recorded in the medical record.
ELDIT diagnoses agreed in 98% of the subjects with
clinical diagnosis of liver disease. The positive predictive
value is the ratio of the number of people that test po-
sitive and have the disease (90) to the total number of
people that test positive (108) in the ELDIT sample. The
positive predictive value was 0.83. That is, 83% of the
subjects on ELDIT will have a diagnosis of liver disease
recorded in their hospital case notes.
5. Discussion
This paper shows that a disease register for a range of
diseases that aﬀect a whole organ can be established by
record linkage as long as there is a common and unique
identiﬁer for each patient and this identiﬁer is used
throughout the health care service. With this, record
linkage is made possible from totally independent data
sources to provide a population-based picture of disease.
Utilising many data sources increases the probability of
a positive diagnosis because each may contribute a
portion to the identiﬁcation of liver disease ﬁlling in the
gaps that others leave.
5.1. Population-based studies versus hospital-based
studies
Population-based studies ﬁnd cases of disease in the
population of a geographical area in a deﬁned period of
time. With properly designed and implemented sampling
procedures an unbiased cohort of subjects can be as-
sembled for study. General population controls ensure
validity when compared with hospital-based studies.
Table 3
Results of the validation study
ELDIT—electronic
algorithm diagnosis
Diagnosis recorded in the medical notes from Ninewells, Perth, and Stracathro hospitals
HbsAg Alc L.D. PBC HAV HCV Cancer ‘‘Nil in notes’’ Total
HBsAg 12 12
Alc L.D. 33 1 34
PBC 1 17 1 5 24
HAV 3 6 9
HCV 24 6 30
Cancer 1 1
Total 12 34 17 3 25 1 18 110
Table 4
Summary of the validation study with agreement and positive predictive value
Diagnosis in medical
notes recorded
No diagnosis in medical
notes recorded
Total
ELDIT agrees with diagnosis in medical notes 90 18 108
ELDIT does not agree with diagnosis in medical notes 2 0 2
Total 92 18 110
Measure of agreement¼ (90/92)¼ 0.98. Positive predictive value¼ (90/108)¼ 0.83.
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Thus, the population-based study can determine the
relative risk, attributable risk, exposure-speciﬁc risks,
and etiologic fraction of the disease in the population
[9]. However, a disadvantage of population-based
studies is that information may not be complete or
found in the population records. Hospital and clinic
records are more likely to have complete notes of
adverse events, biochemistry tests, and information of
interest to the study [10].
In hospital-based studies (population from hospital,
clinic, or medical practice) the cases are found from
convenient lists of potential cases. These cases are not
linked to an underlying population so that a comparator
group must be carefully chosen to ensure an unbiased
analysis. The disadvantage of a hospital-based popula-
tion is that cases may be more severe or advanced in the
disease process. This may lead to an underestimation of
the incidence of disease in the general population [10].
Diseases that begin with ﬂu-like symptoms may not
need medical attention immediately and advice is sought
only after symptoms persist. Because many of the liver
disease are chronic, the insidious onset of the disease
makes it diﬃcult for the incidence of disease to be
calculated.
Nonetheless, utilising the population-based approach
along with many diﬀerent medical record sources elec-
tronically linked, the onset of disease may be more ac-
curately determined and complete records of the disease
process ensured.
5.2. Electronic record-linkage
Other disease management databases have been de-
veloped with record linkage techniques with success.
The diabetes and audit in Tayside Scotland (DARTS)
database record links eight independent data sources to
identify all known diabetic patients in a community. It
was found to have a sensitivity and positive predictive
value of 0.96 and 0.95, respectively, and a point preva-
lence of diabetes of 1.94% [11]. This was higher than
previously reported and may reﬂect the fact that general
practice lists of patients with diabetes are not compre-
hensive.
The ascertainment of liver disease by electronic re-
cord-linkage was maximised because of the unique in-
tegration of multiple sources of data to create a patient
speciﬁc information system. In this study such record
linkage has a number of strengths. First, the speciﬁcity
of virology, immunology, and biochemistry tests in-
creases the completeness of ascertainment of liver dis-
ease. Second, by using the many diﬀerent types of data
sources to identify persons with liver disease increasing
the probability of identiﬁcation. Third, the inhabitants
of Tayside live in a well-deﬁned geographical area of
both rural and inner city communities with a low rate of
migration [2].
5.3. Population-based liver disease
An accurate ﬁgure for the incidence and prevalence of
liver disease and its complications are vital if evidence-
based allocation of health service resources is to be done.
From the health service itself, this knowledge is necessary
to plan hepatology services eﬀectively and eﬃciently. The
data presented in this paper inform us about the preva-
lence of disease in a deﬁned geographical region, the same
region bywhich resources are allocated. It will be possible
with subsequent analysis to account for the health re-
source consumption of these patient groups and stratify
by disease stage. This will allow the health service to
measure the consumption at present and accurately
predict future consumption, providing information on
intervention costs against real costs.
5.4. Identifying undiagnosed liver disease
While this study has identiﬁed over 21,000 patients
with abnormality of liver function, clearly only a small
fraction of these patients have been investigated for liver
disease. This may well be clinically appropriate as the
cause might be obvious to the clinician or related to a
non-liver pathology. However, there are many abnormal
liver function tests that are not followed up, or sub-
sequent liver function tests could be normal. These
patients may be asymptomatic of disease or in a pre-
disease state at the time of abnormal liver function test.
ELDIT has registered all abnormal liver function tests
to follow this cohort of patients longitudinally. This
data set could be viewed as a population-based liver
disease surveillance system where, with suﬃcient follow-
up time, the eventual outcomes and survival of this co-
hort can be determined.
5.5. Implication for creating a liver disease database
As the data supplied by MEMO are registered under
the Data Protection Act for research use only, the EL-
DIT study database, in its current form, is used solely
for anonymised research. There is no external agency
that has or will have access to the data. The data are
kept conﬁdential and restricted for use.
To the best of our knowledge, the ELDIT database is
the ﬁrst population-based register of liver disease in the
United Kingdom. It shows how clinical information can
be harnessed electronically and exploited for the beneﬁt
of patients.
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